Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * BEN-MAIMON CAROLE	2. Date of Event Requiring Statement (MM/DD/YYYY) 5/28/2020	3. Issuer Name and Ticker or Trading Symbol Larimar Therapeutics, Inc. [LRMR]
(Last)        (First)        (Middle) C/O LARIMAR THERAPEUTICS, INC., THREE BALA PLAZA EAST, SUITE 506	4. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director                          _____ 10% Owner ___X___ Officer (give title below)        _____ Other (specify below) President and CEO /
(Street) BALA CYNWYD, PA 19004       (City)              (State)              (Zip)	5. If Amendment, Date Original Filed(MM/DD/YYYY)	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(1)	5/28/2029	Common Stock	133140	$11.73	D
Stock Option (Right to Buy)	(2)	4/10/2027	Common Stock	61419	$11.73	D

Explanation of Responses:
(1)	25% of the Stock Options became exercisable immediately, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date.
(2)	37,107 Stock Options became exercisable immediately, and the remaining 8,957 Stock Options will become exercisable in equal monthly installments on the last day of each of the 7 months immediately following such date, subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date.

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
BEN-MAIMON CAROLE C/O LARIMAR THERAPEUTICS, INC. THREE BALA PLAZA EAST, SUITE 506 BALA CYNWYD, PA 19004	X		President and CEO

Signatures
/s/ Jennifer Johansson, Attorney-in-fact		6/5/2020
**Signature of Reporting Person		Date